1
|
Cummings JE, Abdo Z, Slayden RA. OUP accepted manuscript. JAC Antimicrob Resist 2022; 4:dlac028. [PMID: 35350133 PMCID: PMC8947225 DOI: 10.1093/jacamr/dlac028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2021] [Accepted: 02/27/2022] [Indexed: 12/03/2022] Open
Abstract
Background NIAID has a programme for testing drug candidates against biodefense and emerging bacterial pathogens that uses defined strain panels consisting of standard laboratory reference strains and strains of clinical origin. Objectives The current studies were performed to assess the activity of standard-of-care drugs, determine benchmark criteria for new investigational antibacterial candidate prioritization and identify reduced non-redundant strain panels for candidate performance classification. Methods The susceptibilities of each strain in the screening panels to 40 standard-of-care drugs and clinical drug combinations were determined by percentage growth inhibition using multiple concentrations, a method commonly used in efficient high-throughput screening efforts. The drug susceptibility of each strain was categorized based on interpretive criteria to benchmark the activity of each standard-of-care drug and drug combination, followed by confirmation of select active drugs. Exact match and clustering analyses defined focused non-redundant species and pan-species screening panels. Results This process revealed a broad spectrum of susceptibilities among strains in each species, with important differences between the standard laboratory reference strains and strains of clinical origin. Exact match and clustering analyses identified subsets of non-redundant strains that can more efficiently classify drug activity resulting in individual species screening panels, a pan-species screening panel and a pan-species maximum resistance panel. Conclusions This study resulted in improved non-redundant species screening panels for benchmarking the performance of new investigational antibacterial candidates with the greatest potential for efficacy against clinically relevant Category A and B priority and emerging pathogens.
Collapse
Affiliation(s)
- Jason E. Cummings
- Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, 80523-2025 CO, USA
| | - Zaid Abdo
- Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, 80523-2025 CO, USA
| | | |
Collapse
|
2
|
Sebbane F, Lemaître N. Antibiotic Therapy of Plague: A Review. Biomolecules 2021; 11:724. [PMID: 34065940 PMCID: PMC8151713 DOI: 10.3390/biom11050724] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2021] [Revised: 05/04/2021] [Accepted: 05/07/2021] [Indexed: 12/15/2022] Open
Abstract
Plague-a deadly disease caused by the bacterium Yersinia pestis-is still an international public health concern. There are three main clinical forms: bubonic plague, septicemic plague, and pulmonary plague. In all three forms, the symptoms appear suddenly and progress very rapidly. Early antibiotic therapy is essential for countering the disease. Several classes of antibiotics (e.g., tetracyclines, fluoroquinolones, aminoglycosides, sulfonamides, chloramphenicol, rifamycin, and β-lactams) are active in vitro against the majority of Y. pestis strains and have demonstrated efficacy in various animal models. However, some discrepancies have been reported. Hence, health authorities have approved and recommended several drugs for prophylactic or curative use. Only monotherapy is currently recommended; combination therapy has not shown any benefits in preclinical studies or case reports. Concerns about the emergence of multidrug-resistant strains of Y. pestis have led to the development of new classes of antibiotics and other therapeutics (e.g., LpxC inhibitors, cationic peptides, antivirulence drugs, predatory bacteria, phages, immunotherapy, host-directed therapy, and nutritional immunity). It is difficult to know which of the currently available treatments or therapeutics in development will be most effective for a given form of plague. This is due to the lack of standardization in preclinical studies, conflicting data from case reports, and the small number of clinical trials performed to date.
Collapse
Affiliation(s)
- Florent Sebbane
- Univ. Lille, Inserm, CNRS, Institut Pasteur Lille, U1019—UMR 9017—CIIL—Center for Infection and Immunity of Lille, F-59000 Lille, France
| | - Nadine Lemaître
- Univ. Lille, Inserm, CNRS, Institut Pasteur Lille, U1019—UMR 9017—CIIL—Center for Infection and Immunity of Lille, F-59000 Lille, France
- Laboratoire de Bactériologie-Hygiène, Centre Hospitalier Universitaire Amiens Picardie, UR 4294, Agents Infectieux, Résistance et Chimiothérapie (AGIR), Université de Picardie Jules Verne, F-80000 Amiens, France
| |
Collapse
|
3
|
Neelakantan H, Vance V, Wang HYL, McHardy SF, Watowich SJ. Noncoupled Fluorescent Assay for Direct Real-Time Monitoring of Nicotinamide N-Methyltransferase Activity. Biochemistry 2017; 56:824-832. [DOI: 10.1021/acs.biochem.6b01215] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Affiliation(s)
- Harshini Neelakantan
- Department
of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, Texas 77555, United States
| | - Virginia Vance
- Department
of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, Texas 77555, United States
| | - Hua-Yu Leo Wang
- Center
for Innovative Drug Discovery, Department of Chemistry, University of Texas at San Antonio, San Antonio, Texas 78249, United States
| | - Stanton F. McHardy
- Center
for Innovative Drug Discovery, Department of Chemistry, University of Texas at San Antonio, San Antonio, Texas 78249, United States
| | - Stanley J. Watowich
- Department
of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, Texas 77555, United States
| |
Collapse
|
4
|
Ward MS, Silva I, Martinez W, Jefferson J, Rahman S, Garcia JM, Kanichar D, Roppiyakuda L, Kosmowska E, Faust MA, Tran KP, Chow F, Buglo E, Zhou F, Groziak MP, Xu HH. Identification of cellular targets of a series of boron heterocycles using TIPA II-A sensitive target identification platform. Bioorg Med Chem 2016; 24:3267-75. [PMID: 27301675 DOI: 10.1016/j.bmc.2016.05.058] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2016] [Revised: 05/23/2016] [Accepted: 05/28/2016] [Indexed: 11/24/2022]
Abstract
One of the hurdles in the discovery of antibiotics is the difficulty of linking antibacterial compounds to their cellular targets. Our laboratory has employed a genome-wide approach of over-expressing essential genes in order to identify cellular targets of antibacterial inhibitors. Our objective in this project was to develop and validate a more sensitive disk diffusion based platform of target identification (Target Identification Platform for Antibacterials version 2; TIPA II) using a collection of cell clones in an Escherichia coli mutant (AS19) host with increased outer membrane permeability. Five known antibiotics/inhibitors and 28 boron heterocycles were tested by TIPA II assay, in conjunction with the original assay TIPA. The TIPA II was more sensitive than TIPA because eight boron heterocycles previously found to be inactive to AG1 cells in TIPA assays exhibited activity to AS19 cells. For 15 boron heterocycles, resistant colonies were observed within the zones of inhibition only on the inducing plates in TIPA II assays. DNA sequencing confirmed that resistant clones harbor plasmids with fabI gene as insert, indicating that these boron heterocycles all target enoyl ACP reductase. Additionally, cell-based assays and dose response curved obtained indicated that for two boron heterocycle inhibitors, the fabI cell clone in AG1 (wild-type) host cells exhibited at least 11 fold more resistance under induced conditions than under non-induced conditions. Moreover, TIPA II also identified cellular targets of known antibacterial inhibitors triclosan, phosphomycin, trimethoprim, diazaborine and thiolactomycin, further validating the utility of the new system.
Collapse
Affiliation(s)
- Matthew S Ward
- Department of Biological Sciences, California State University Los Angeles, Los Angeles, CA 90032, USA
| | - Isba Silva
- Department of Biological Sciences, California State University Los Angeles, Los Angeles, CA 90032, USA
| | - Walfre Martinez
- Department of Biological Sciences, California State University Los Angeles, Los Angeles, CA 90032, USA
| | - Jameka Jefferson
- Department of Biological Sciences, California State University Los Angeles, Los Angeles, CA 90032, USA
| | - Shakila Rahman
- Department of Biological Sciences, California State University Los Angeles, Los Angeles, CA 90032, USA
| | - Jeanie M Garcia
- Department of Biological Sciences, California State University Los Angeles, Los Angeles, CA 90032, USA
| | - Divya Kanichar
- Department of Chemistry and Biochemistry, California State University East Bay, Hayward, CA 94542, USA
| | - Lance Roppiyakuda
- Department of Chemistry and Biochemistry, California State University East Bay, Hayward, CA 94542, USA
| | - Ewa Kosmowska
- Department of Chemistry and Biochemistry, California State University East Bay, Hayward, CA 94542, USA
| | - Michelle A Faust
- Department of Chemistry and Biochemistry, California State University East Bay, Hayward, CA 94542, USA
| | - Kim P Tran
- Department of Chemistry and Biochemistry, California State University East Bay, Hayward, CA 94542, USA
| | - Felicia Chow
- Department of Chemistry and Biochemistry, California State University East Bay, Hayward, CA 94542, USA
| | - Elena Buglo
- Department of Chemistry and Biochemistry, California State University East Bay, Hayward, CA 94542, USA
| | - Feimeng Zhou
- Department of Chemistry and Biochemistry, California State University Los Angeles, Los Angeles, CA 90032, USA
| | - Michael P Groziak
- Department of Chemistry and Biochemistry, California State University East Bay, Hayward, CA 94542, USA
| | - H Howard Xu
- Department of Biological Sciences, California State University Los Angeles, Los Angeles, CA 90032, USA.
| |
Collapse
|
5
|
Abstract
Francisella tularensis is a category A bioterrorism agent. It is the etiological agent of tularemia, a zoonotic disease found throughout the northern hemisphere. The intentional spread of F. tularensis aerosols would probably lead to severe and often fatal pneumonia cases, but also secondary cases from contaminated animals and environments. We are not ready to face such a situation. No vaccine is currently available. A few antibiotics are active against F. tularensis, but strains resistant to these antibiotics could be used in the context of bioterrorism. We need new therapeutic strategies to fight against category A bioterrorism agents, including development of new drugs inhibiting F. tularensis growth and/or virulence, or enhancing the host response to infection by this pathogen.
Collapse
Affiliation(s)
- Max Maurin
- Centre National de Référence des Francisella, Département des Agents Infectieux, Institut de Biologie et de Pathologie, CHU de Grenoble, F-38043, Grenoble, France
| |
Collapse
|